title: Development of cutaneous sarcoidosis during treatment with tumour necrosis alpha factor antagonists.
abstract: The use of tumour necrosis factor alpha (TNF-α) antagonists is increasing in the field of dermatology. These agents have been used for multiple inflammatory and immune skin conditions, but most notably, psoriasis. Adverse effects of anti-TNF-α agents have been reported, including the paradoxical development of sarcoidosis. We present an unusual case of limited cutaneous sarcoidosis developing while the patient was on etanercept therapy, and a review of the current literature.
authors.affiliation: Department of Dermatology, Royal North Shore Hospital, St Leonards, NSW 2065, Australia. elamrock@gmail.com
authors.forename: Edwina
authors.initials: E
authors.lastname: Lamrock
authors.forename: Pam
authors.initials: P
authors.lastname: Brown
mesh_terms: D015535:Arthritis, Psoriatic / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D012507:Sarcoidosis / Q000139:chemically induced*; D012871:Skin Diseases / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept